EA004701B1 - Амиды антраниловой кислоты и их применение в качестве лекарственных средств - Google Patents
Амиды антраниловой кислоты и их применение в качестве лекарственных средств Download PDFInfo
- Publication number
- EA004701B1 EA004701B1 EA200100524A EA200100524A EA004701B1 EA 004701 B1 EA004701 B1 EA 004701B1 EA 200100524 A EA200100524 A EA 200100524A EA 200100524 A EA200100524 A EA 200100524A EA 004701 B1 EA004701 B1 EA 004701B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- group
- phenyl
- methyl
- hydrogen
- stands
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9824579.8A GB9824579D0 (en) | 1998-11-10 | 1998-11-10 | Organic compounds |
DE1999110396 DE19910396C2 (de) | 1999-03-03 | 1999-03-03 | Anthranilsäureamide und deren Verwendung als Arzneimittel |
PCT/EP1999/008478 WO2000027819A2 (de) | 1998-11-10 | 1999-11-09 | Anthranilsäureamide und deren verwendung als arzneimittel |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200100524A1 EA200100524A1 (ru) | 2002-02-28 |
EA004701B1 true EA004701B1 (ru) | 2004-06-24 |
Family
ID=26052266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200100524A EA004701B1 (ru) | 1998-11-10 | 1999-11-09 | Амиды антраниловой кислоты и их применение в качестве лекарственных средств |
Country Status (23)
Families Citing this family (153)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1140903B1 (en) * | 1998-12-23 | 2004-08-04 | Eli Lilly And Company | Aromatic amides |
DE10023485A1 (de) * | 2000-05-09 | 2001-11-22 | Schering Ag | Anthranylalkyl- und -cycloalkylamide und deren Verwendung als Arzneimittel |
DE10023484A1 (de) | 2000-05-09 | 2001-11-22 | Schering Ag | Anthranylamide und deren Verwendung als Arzneimittel |
DE10023486C1 (de) | 2000-05-09 | 2002-03-14 | Schering Ag | Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel |
AU8181701A (en) * | 2000-06-21 | 2002-01-02 | Hoffmann La Roche | Benzothiazole derivatives |
JP2004521878A (ja) * | 2000-12-07 | 2004-07-22 | スィーヴィー セラピューティクス インコーポレイテッド | Abca−1を上昇させる化合物 |
US20030134836A1 (en) | 2001-01-12 | 2003-07-17 | Amgen Inc. | Substituted arylamine derivatives and methods of use |
US7102009B2 (en) * | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
US6995162B2 (en) * | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
US20020147198A1 (en) * | 2001-01-12 | 2002-10-10 | Guoqing Chen | Substituted arylamine derivatives and methods of use |
CN104116738A (zh) | 2001-02-19 | 2014-10-29 | 诺华股份有限公司 | 癌症的治疗 |
US6864255B2 (en) | 2001-04-11 | 2005-03-08 | Amgen Inc. | Substituted triazinyl amide derivatives and methods of use |
JP2004528379A (ja) * | 2001-05-08 | 2004-09-16 | シエーリング アクチエンゲゼルシャフト | Vegfr−2およびvegfr−3インヒビターとしての選択的アントラニルアミドピリジンアミド |
DE10123587B4 (de) * | 2001-05-08 | 2005-04-07 | Schering Ag | Cyanoanthranylamid-Derivate und deren Verwendung als Arzneimittel |
DE10123573B4 (de) * | 2001-05-08 | 2005-06-02 | Schering Ag | N-Oxidanthranylamid-Derivate und deren Verwendung als Arzneimittel |
US7459470B2 (en) | 2001-05-08 | 2008-12-02 | Schering Ag | N-oxide anthranylamide derivatives and their use as medicaments |
WO2003000678A1 (de) * | 2001-05-08 | 2003-01-03 | Schering Aktiengesellschaft | Cyanoanthranylamid-derivate und deren verwendung als arzneimittel |
AU2002342335B2 (en) | 2001-05-16 | 2006-02-02 | Novartis Ag | Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent |
US7199147B2 (en) | 2001-06-12 | 2007-04-03 | Dainippon Sumitomo Pharma Co., Ltd. | Rho kinase inhibitors |
TWI315982B (en) | 2001-07-19 | 2009-10-21 | Novartis Ag | Combinations comprising epothilones and pharmaceutical uses thereof |
JP4445262B2 (ja) | 2001-10-09 | 2010-04-07 | アムジェン インコーポレイテッド | 抗炎症剤としてのイミダゾール誘導体 |
GB0126902D0 (en) * | 2001-11-08 | 2002-01-02 | Novartis Ag | Organic compounds |
GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
EP1944026B1 (en) | 2002-05-16 | 2013-06-26 | Novartis AG | Use of EDG receptor binding agents in cancer |
US7307088B2 (en) | 2002-07-09 | 2007-12-11 | Amgen Inc. | Substituted anthranilic amide derivatives and methods of use |
US7094789B2 (en) | 2002-07-22 | 2006-08-22 | Asahi Kasei Pharma Corporation | 5-substituted isoquinoline derivatives |
US7615565B2 (en) | 2002-07-31 | 2009-11-10 | Bayer Schering Pharma Aktiengesellschaft | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines |
DE10235690A1 (de) * | 2002-07-31 | 2004-02-19 | Schering Ag | VEGFR-2 und VEGFR-3 inhibitorische Anthranylamidpyridinamide |
US7338956B2 (en) | 2002-08-07 | 2008-03-04 | Sanofi-Aventis Deutschland Gmbh | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
EP1388341A1 (en) * | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
DE60329030D1 (de) * | 2002-12-04 | 2009-10-08 | Ore Pharmaceuticals Inc | Melanocortin-rezeptormodulatoren |
US7696225B2 (en) | 2003-01-06 | 2010-04-13 | Osi Pharmaceuticals, Inc. | (2-carboxamido)(3-Amino) thiophene compounds |
TWI299664B (en) | 2003-01-06 | 2008-08-11 | Osi Pharm Inc | (2-carboxamido)(3-amino)thiophene compounds |
US7087761B2 (en) | 2003-01-07 | 2006-08-08 | Hoffmann-La Roche Inc. | Cyclization process for substituted benzothiazole derivatives |
US20040192728A1 (en) * | 2003-02-03 | 2004-09-30 | Ellen Codd | Quinoline-derived amide modulators of vanilloid VR1 receptor |
EP1606289B1 (en) | 2003-02-14 | 2009-12-02 | Glaxo Group Limited | Carboxamide derivatives |
US7534802B2 (en) | 2003-03-07 | 2009-05-19 | Santen Pharmaceutical Co., Ltd. | Compounds having 4-pyridylalkylthio group as substituent |
AR044402A1 (es) | 2003-05-19 | 2005-09-14 | Irm Llc | Compuestos heterociclicos y su uso como inmunodepresores. composiciones farmaceuticas que los contienen. |
MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
US20050004133A1 (en) * | 2003-06-05 | 2005-01-06 | Makings Lewis R. | Modulators of VR1 receptor |
US7202260B2 (en) * | 2003-06-13 | 2007-04-10 | Schering Ag | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones |
DE10327719A1 (de) * | 2003-06-13 | 2005-01-20 | Schering Ag | VEGFR-2 und VEGFR-3 Inhibitorische Anthranylamidpyridone |
US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
WO2006074147A2 (en) | 2005-01-03 | 2006-07-13 | Myriad Genetics, Inc. | Nitrogen containing bicyclic compounds and therapeutical use thereof |
ES2380201T3 (es) * | 2003-07-11 | 2012-05-09 | Merck Patent Gmbh | Derivados de benzimidazol |
GB0326601D0 (en) * | 2003-11-14 | 2003-12-17 | Novartis Ag | Organic compounds |
UA89035C2 (ru) | 2003-12-03 | 2009-12-25 | Лео Фарма А/С | Эфиры гидроксамовых кислот и их фармацевтическое применение |
KR101179840B1 (ko) | 2004-02-17 | 2012-09-04 | 산텐 세이야꾸 가부시키가이샤 | 치환 또는 무치환 아미노기를 도입한 4-피리딜알킬티오기를갖는 신규 고리형 화합물 |
DE102004009238A1 (de) * | 2004-02-26 | 2005-09-08 | Merck Patent Gmbh | Arylamid-Derivate |
EP1568368A1 (en) * | 2004-02-26 | 2005-08-31 | Schering Aktiengesellschaft | Pharmaceutical combination comprising a CDK inhibitor and a VEGF receptor inhibitor |
WO2005085188A2 (en) * | 2004-03-02 | 2005-09-15 | Compass Pharmaceuticals Llc | Compounds and methods for anti-tumor therapy |
US7427390B2 (en) * | 2004-03-10 | 2008-09-23 | Schering Ag | Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy |
DE102004011720B4 (de) * | 2004-03-10 | 2008-04-03 | Bayer Schering Pharma Aktiengesellschaft | Radiohalogenierte Benzamidderivate und deren Verwendung in der Tumordiagnostik und Tumortherapie |
EA011279B1 (ru) | 2004-05-24 | 2009-02-27 | Ф. Хоффманн-Ля Рош Аг | (4-метокси-7-морфолин-4-илбензотиазол-2-ил)-амид 4-гидрокси-4-метилпиперидин-1-карбоновой кислоты |
DE102004039876A1 (de) * | 2004-06-23 | 2006-01-26 | Lanxess Deutschland Gmbh | Herstellung von fluorierten 1,3-Benzodioxanen |
GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
BRPI0515594B8 (pt) | 2004-09-22 | 2021-05-25 | Janssen Pharmaceutica Nv | compostos inibidores da interação entre mdm2 e p53,composição farmacêutica, processo para a preparação desta composição farmacêutica, usos dos compostos, suas combinações e processo para a preparação destes compostos |
US7906533B2 (en) * | 2004-11-03 | 2011-03-15 | Bayer Schering Pharma Ag | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
EP1655297A1 (en) * | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
EP1657241A1 (en) | 2004-11-03 | 2006-05-17 | Schering Aktiengesellschaft | Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
EP1655295A1 (en) * | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
EP1812392B1 (en) | 2004-11-05 | 2008-07-09 | F.Hoffmann-La Roche Ag | Process for preparation of isonicotinic acid derivatives |
US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
WO2006093253A1 (ja) * | 2005-03-03 | 2006-09-08 | Santen Pharmaceutical Co., Ltd. | キノリルアルキルチオ基を有する新規環式化合物 |
BRPI0609719B8 (pt) | 2005-03-23 | 2021-05-25 | Hoffmann La Roche | derivados de acetilenil-pirazol-pirimidina como antagonistas de mgbur2 |
WO2006106914A1 (ja) | 2005-03-31 | 2006-10-12 | Santen Pharmaceutical Co., Ltd. | ピリミジニルアルキルチオ基を有する新規環式化合物 |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
CN101273040B (zh) | 2005-09-27 | 2011-11-09 | 弗·哈夫曼-拉罗切有限公司 | 作为mglur2拮抗剂的*二唑基吡唑并嘧啶类化合物 |
RU2008116314A (ru) | 2005-09-27 | 2009-11-10 | Новартис АГ (CH) | Соединения карбоксамина и их применение для лечения hdac-зависимых заболеваний |
US8247556B2 (en) * | 2005-10-21 | 2012-08-21 | Amgen Inc. | Method for preparing 6-substituted-7-aza-indoles |
CA2933875C (en) | 2005-11-21 | 2018-06-26 | Novartis Ag | 40-o-(2-hydroxyethyl)-rapamycin for use as a sole drug substance in the treatment of carcinoid tumors arising from the foregut, midgut, or hindgut |
JP5169220B2 (ja) * | 2005-11-30 | 2013-03-27 | アステラス製薬株式会社 | 2−アミノベンズアミド誘導体 |
CA2644649C (en) | 2006-03-22 | 2014-06-17 | Janssen Pharmaceutica N.V. | Cyclic-alkylaminederivatives as inhibitors of the interaction between mdm2 and p53 |
CA2644643C (en) | 2006-03-22 | 2015-05-19 | Janssen Pharmaceutica N.V. | Inhibitors of the interaction between mdm2 and p53 |
KR20140019032A (ko) | 2006-04-05 | 2014-02-13 | 노파르티스 아게 | 암을 치료하기 위한 치료제의 조합물 |
KR20090007635A (ko) | 2006-05-09 | 2009-01-19 | 노파르티스 아게 | 철 킬레이터 및 항-신생물 약제를 포함하는 조합물 및 그의용도 |
GB0612721D0 (en) | 2006-06-27 | 2006-08-09 | Novartis Ag | Organic compounds |
ATE502943T1 (de) | 2006-09-29 | 2011-04-15 | Novartis Ag | Pyrazolopyrimidine als pi3k-lipidkinasehemmer |
WO2008077809A1 (en) * | 2006-12-22 | 2008-07-03 | F. Hoffmann-La Roche Ag | Process for the manufacture of 7-oxa-bicyclo derivatives |
JP5216341B2 (ja) | 2007-01-29 | 2013-06-19 | 参天製薬株式会社 | 血管新生阻害活性を有する新規オキサジアゾール誘導体およびチアジアゾール誘導体 |
US20100069458A1 (en) | 2007-02-15 | 2010-03-18 | Peter Wisdom Atadja | Combination of lbh589 with other therapeutic agents for treating cancer |
EP1975166A1 (en) * | 2007-03-30 | 2008-10-01 | Bayer Schering Pharma AG | Synthesis of anthranilamides |
TW200922557A (en) | 2007-08-06 | 2009-06-01 | Janssen Pharmaceutica Nv | Substituted phenylenediamines as inhibitors of the interaction between MDM2 and p53 |
KR101252349B1 (ko) | 2008-03-26 | 2013-04-08 | 노파르티스 아게 | 데아세틸라제 b의 히드록사메이트-기재 억제제 |
CA2734551A1 (en) | 2008-08-27 | 2010-03-04 | Leo Pharma A/S | Pyridine derivatives as vegfr-2 receptor and protein tyrosine kinase inhibitors |
EP2344161B1 (en) | 2008-10-16 | 2018-12-19 | Celator Pharmaceuticals, Inc. | Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab |
MY152669A (en) | 2008-12-18 | 2014-10-31 | Novartis Ag | Hemifumarate salt of 1-[4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-azetidine-3-carboxylic acid |
US8173634B2 (en) | 2008-12-18 | 2012-05-08 | Novartis Ag | Polymorphic form of 1-(4-{1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl}-2-ethyl-benzyl)-azetidine-3-carboxylic |
BRPI0922466A2 (pt) | 2008-12-18 | 2018-10-23 | Novartis Ag | sais |
TW201031406A (en) | 2009-01-29 | 2010-09-01 | Novartis Ag | Substituted benzimidazoles for the treatment of astrocytomas |
NZ594186A (en) | 2009-02-04 | 2012-12-21 | Janssen Pharmaceutica Nv | Indole derivatives as anticancer agents |
SG176105A1 (en) | 2009-06-26 | 2011-12-29 | Novartis Ag | 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17 |
US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
AU2010283806A1 (en) | 2009-08-12 | 2012-03-01 | Novartis Ag | Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation |
CA2771532C (en) | 2009-08-17 | 2021-03-23 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
AU2010284972A1 (en) | 2009-08-20 | 2012-03-08 | Novartis Ag | Heterocyclic oxime compounds |
IN2012DN01693A (US07122547-20061017-C00034.png) | 2009-08-26 | 2015-06-05 | Novartis Ag | |
CA2773661A1 (en) | 2009-09-10 | 2011-03-17 | Novartis Ag | Ether derivatives of bicyclic heteroaryls |
KR101398772B1 (ko) | 2009-11-04 | 2014-05-27 | 노파르티스 아게 | Mek 억제제로서 유용한 헤테로시클릭 술폰아미드 유도체 |
JP2013512215A (ja) | 2009-11-25 | 2013-04-11 | ノバルティス アーゲー | 二環式ヘテロアリールのベンゼン縮合6員酸素含有ヘテロ環誘導体 |
EA201200823A1 (ru) | 2009-12-08 | 2013-02-28 | Новартис Аг | Гетероциклические производные сульфонамидов |
US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
CU24130B1 (es) | 2009-12-22 | 2015-09-29 | Novartis Ag | Isoquinolinonas y quinazolinonas sustituidas |
US20130090342A1 (en) | 2010-06-17 | 2013-04-11 | Novartis Ag | Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives |
US20130085161A1 (en) | 2010-06-17 | 2013-04-04 | Novartis Ag | Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives |
US20130102477A1 (en) | 2010-06-23 | 2013-04-25 | Ryan D. Morin | Biomarkers for non-hodgkin lymphomas and uses thereof |
US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
CA2810998C (en) | 2010-09-10 | 2024-04-09 | Robert Allen Copeland | Inhibitors of human ezh2, and methods of use thereof |
CN103108871B (zh) | 2010-09-16 | 2014-09-10 | 诺华股份有限公司 | 17α-羟化酶/C17,20-裂合酶抑制剂 |
US20130324526A1 (en) | 2011-02-10 | 2013-12-05 | Novartis Ag | [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase |
WO2012116237A2 (en) | 2011-02-23 | 2012-08-30 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
EP2681216B1 (en) | 2011-02-28 | 2017-09-27 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
EP2683722A1 (en) | 2011-03-08 | 2014-01-15 | Novartis AG | Fluorophenyl bicyclic heteroaryl compounds |
TWI598336B (zh) | 2011-04-13 | 2017-09-11 | 雅酶股份有限公司 | 經取代之苯化合物 |
JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
MX359399B (es) | 2011-04-28 | 2018-09-27 | Novartis Ag | Inhibidores de 17alfa-hidroxilasa/c17-20-liasa. |
KR20140034898A (ko) | 2011-06-09 | 2014-03-20 | 노파르티스 아게 | 헤테로시클릭 술폰아미드 유도체 |
US8859535B2 (en) | 2011-06-20 | 2014-10-14 | Novartis Ag | Hydroxy substituted isoquinolinone derivatives |
WO2012175487A1 (en) | 2011-06-20 | 2012-12-27 | Novartis Ag | Cyclohexyl isoquinolinone compounds |
ES2691650T3 (es) | 2011-09-15 | 2018-11-28 | Novartis Ag | 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como inhibidores de tirosina quinasa c-Met |
WO2013080141A1 (en) | 2011-11-29 | 2013-06-06 | Novartis Ag | Pyrazolopyrrolidine compounds |
EA201491259A1 (ru) | 2011-12-23 | 2014-11-28 | Новартис Аг | Соединения и композиции для ингибирования взаимодействия bcl2 с партнерами связывания |
EA201491260A1 (ru) | 2011-12-23 | 2014-11-28 | Новартис Аг | Соединения и композиции для ингибирования взаимодействия bcl2 с партнерами по связыванию |
CA2859862A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
CN104136429A (zh) | 2011-12-23 | 2014-11-05 | 诺华股份有限公司 | 用于抑制bcl2与结合配偶体相互作用的化合物 |
AU2012355623A1 (en) | 2011-12-23 | 2014-07-17 | Novartis Ag | Compounds for inhibiting the interaction of BCL2 with binding partners |
CN102603729A (zh) * | 2012-01-12 | 2012-07-25 | 贵州大学 | N-(2-(取代苯并噻唑-2-氨基甲酰基)-取代苯基)吡啶甲酰胺类衍生物 |
US8815926B2 (en) | 2012-01-26 | 2014-08-26 | Novartis Ag | Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases |
WO2013138753A1 (en) | 2012-03-16 | 2013-09-19 | Fox Chase Chemical Diversity Center, Inc. | Prodrugs of riluzole and their method of use |
US20150297604A1 (en) | 2012-04-03 | 2015-10-22 | Novartis Ag | Combination Products with Tyrosine Kinase Inhibitors and their Use |
MX362339B (es) | 2012-04-13 | 2019-01-11 | Epizyme Inc | Forma de sal de un inhibidor de histona metiltransferasa humana ezh2. |
CN104321325B (zh) | 2012-05-24 | 2016-11-16 | 诺华股份有限公司 | 吡咯并吡咯烷酮化合物 |
BR112015008480A2 (pt) | 2012-10-15 | 2017-07-04 | Epizyme Inc | compostos de benzeno substituído |
WO2014115077A1 (en) | 2013-01-22 | 2014-07-31 | Novartis Ag | Substituted purinone compounds |
US9556180B2 (en) | 2013-01-22 | 2017-01-31 | Novartis Ag | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction |
JP2016512835A (ja) | 2013-03-15 | 2016-05-09 | インテリカイン, エルエルシー | キナーゼ阻害剤の組み合わせ及びそれらの使用 |
CN103130696B (zh) * | 2013-03-21 | 2014-06-11 | 山东大学 | 邻氨基苯甲酰胺类化合物及其制备方法与应用 |
WO2014155268A2 (en) | 2013-03-25 | 2014-10-02 | Novartis Ag | Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity |
WO2015022664A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
WO2015022663A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
US9227969B2 (en) | 2013-08-14 | 2016-01-05 | Novartis Ag | Compounds and compositions as inhibitors of MEK |
CN103405434A (zh) * | 2013-08-22 | 2013-11-27 | 中国药科大学 | Vegfr-2抑制剂及其用途 |
MX2016004703A (es) | 2013-10-16 | 2017-02-28 | Epizyme Inc | Forma salina de hidrocloruro para la inhibicion de ezh2. |
CN104163794A (zh) * | 2013-10-17 | 2014-11-26 | 中国药科大学 | 2-氨基芳环类血管内皮生长因子受体(vegfr)抑制剂及其制备方法和用途 |
WO2015084804A1 (en) | 2013-12-03 | 2015-06-11 | Novartis Ag | Combination of mdm2 inhibitor and braf inhibitor and their use |
JP6526789B2 (ja) | 2014-07-31 | 2019-06-05 | ノバルティス アーゲー | 組み合わせ療法 |
US20210128615A1 (en) | 2017-10-18 | 2021-05-06 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Methods and compounds for improved immune cell therapy |
JP7021356B2 (ja) | 2017-12-21 | 2022-02-16 | ヘフェイ インスティテューツ オブ フィジカル サイエンス, チャイニーズ アカデミー オブ サイエンシーズ | ピリミジン誘導体系キナーゼ阻害剤類 |
EP4058465A1 (en) | 2019-11-14 | 2022-09-21 | Cohbar Inc. | Cxcr4 antagonist peptides |
AU2020417293A1 (en) | 2020-01-03 | 2022-09-01 | Berg Llc | Polycyclic amides as UBE2K modulators for treating cancer |
WO2022222890A1 (en) * | 2021-04-19 | 2022-10-27 | Shanghai Yao Yuan Biotechnology Co., Ltd. | Benzothiazole and quinoline derivatives for use in treating kawasaki disease |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3226394A (en) * | 1964-06-16 | 1965-12-28 | Shulton Inc | Pyridylethylated anthranilamides and derivatives thereof |
US3409668A (en) | 1964-11-07 | 1968-11-05 | Palazzo Giuseppe | Substituted anthranilamides and process for the preparation thereof |
JPS5744672B2 (US07122547-20061017-C00034.png) | 1974-05-24 | 1982-09-22 | ||
DE2652144A1 (de) | 1976-11-16 | 1978-05-18 | Merck Patent Gmbh | Neue chinazolindione |
US4568687A (en) | 1983-02-28 | 1986-02-04 | American Cyanamid Company | N-[2-4-(1H-Imidazol-1-yl)alkyl]-arylamides and pharmaceutical compositions |
EP0117462A3 (en) | 1983-02-28 | 1986-08-20 | American Cyanamid Company | N-(2-4-(1h-imidazol-1-yl)alkyl)arylamides |
FR2689508B1 (fr) * | 1992-04-01 | 1994-06-17 | Fournier Ind & Sante | Derives de l'imidazole, leur procede de preparation et leur application en therapeutique. |
CN1118595A (zh) * | 1993-12-27 | 1996-03-13 | 卫材株式会社 | 氨茴酸衍生物 |
DE59710417D1 (de) * | 1996-03-15 | 2003-08-14 | Novartis Ag | N-7 HETEROCYCLYL-PYRROLO[ 2,3-d]PYRIMIDINE UND IHRE VERWENDUNG |
-
1999
- 1999-09-11 UA UA2001063917A patent/UA71587C2/uk unknown
- 1999-11-09 PL PL99348349A patent/PL348349A1/xx not_active Application Discontinuation
- 1999-11-09 CA CA002350208A patent/CA2350208A1/en not_active Abandoned
- 1999-11-09 US US09/831,506 patent/US7122547B1/en not_active Expired - Fee Related
- 1999-11-09 WO PCT/EP1999/008478 patent/WO2000027819A2/de not_active Application Discontinuation
- 1999-11-09 KR KR1020017005800A patent/KR100777476B1/ko not_active IP Right Cessation
- 1999-11-09 KR KR1020077015852A patent/KR100855396B1/ko not_active IP Right Cessation
- 1999-11-09 TR TR2001/01307T patent/TR200101307T2/xx unknown
- 1999-11-09 EE EEP200100258A patent/EE200100258A/xx unknown
- 1999-11-09 AU AU10454/00A patent/AU771180B2/en not_active Ceased
- 1999-11-09 CZ CZ20011631A patent/CZ20011631A3/cs unknown
- 1999-11-09 SK SK607-2001A patent/SK6072001A3/sk unknown
- 1999-11-09 BR BR9915553-2A patent/BR9915553A/pt not_active Application Discontinuation
- 1999-11-09 NZ NZ511413A patent/NZ511413A/en unknown
- 1999-11-09 YU YU31801A patent/YU31801A/sh unknown
- 1999-11-09 EA EA200100524A patent/EA004701B1/ru not_active IP Right Cessation
- 1999-11-09 EP EP99953967A patent/EP1129074A2/de not_active Withdrawn
- 1999-11-09 HU HU0104425A patent/HUP0104425A3/hu unknown
- 1999-11-09 CN CNB998130788A patent/CN1151133C/zh not_active Expired - Fee Related
- 1999-11-09 JP JP2000580999A patent/JP2002529452A/ja not_active Withdrawn
-
2001
- 2001-05-07 NO NO20012245A patent/NO320647B1/no unknown
- 2001-05-25 HR HR20010402A patent/HRP20010402A2/hr not_active Application Discontinuation
- 2001-06-11 BG BG105588A patent/BG65371B1/bg unknown
-
2002
- 2002-05-14 HK HK02103628A patent/HK1041882A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
BG105588A (en) | 2002-04-30 |
WO2000027819A3 (de) | 2000-08-17 |
HRP20010402A2 (en) | 2003-10-31 |
YU31801A (sh) | 2003-12-31 |
CN1325384A (zh) | 2001-12-05 |
AU1045400A (en) | 2000-05-29 |
NZ511413A (en) | 2004-01-30 |
UA71587C2 (uk) | 2004-12-15 |
KR20070087027A (ko) | 2007-08-27 |
NO20012245D0 (no) | 2001-05-07 |
KR20010075689A (ko) | 2001-08-09 |
TR200101307T2 (tr) | 2002-05-21 |
JP2002529452A (ja) | 2002-09-10 |
HK1041882A1 (en) | 2002-07-26 |
EA200100524A1 (ru) | 2002-02-28 |
US7122547B1 (en) | 2006-10-17 |
BR9915553A (pt) | 2001-08-14 |
AU771180B2 (en) | 2004-03-18 |
CA2350208A1 (en) | 2000-05-18 |
HUP0104425A3 (en) | 2003-05-28 |
NO20012245L (no) | 2001-07-10 |
BG65371B1 (bg) | 2008-04-30 |
PL348349A1 (en) | 2002-05-20 |
EE200100258A (et) | 2002-12-16 |
CN1151133C (zh) | 2004-05-26 |
KR100855396B1 (ko) | 2008-08-29 |
SK6072001A3 (en) | 2002-01-07 |
EP1129074A2 (de) | 2001-09-05 |
CZ20011631A3 (cs) | 2001-10-17 |
WO2000027819A2 (de) | 2000-05-18 |
HUP0104425A2 (hu) | 2002-03-28 |
KR100777476B1 (ko) | 2007-11-16 |
NO320647B1 (no) | 2006-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA004701B1 (ru) | Амиды антраниловой кислоты и их применение в качестве лекарственных средств | |
RU2353618C2 (ru) | Замещенные амиды бензойной кислоты и их содержащий фармацевтический препарат | |
RU2264399C2 (ru) | Замещенные в ортоположении амиды антраниловой кислоты и их применение в качестве лекарственных средств | |
JP2002529452A5 (US07122547-20061017-C00034.png) | ||
US6818661B2 (en) | Anthranylalkyl and cycloalkyl amides and use thereof as VEGF receptor inhibitors | |
US20080275057A1 (en) | Compounds with anti-cancer activity | |
ZA200104673B (en) | Antrhranilic acid amides and the use thereof as medicaments. | |
JP2003533450A (ja) | アントラニルアミドおよび製剤としてのそれらの使用 | |
JP4343681B2 (ja) | シアノアントラニルアミド誘導体およびそれらの薬剤としての使用 | |
EP1389201A1 (de) | N-oxidanthranylamid-derivate und deren verwendung als arzneimittel | |
DE19910396C2 (de) | Anthranilsäureamide und deren Verwendung als Arzneimittel | |
MXPA01004692A (en) | Antrhranilic acid amides and the use thereof as medicaments | |
DE10123573B4 (de) | N-Oxidanthranylamid-Derivate und deren Verwendung als Arzneimittel | |
DE10125293A1 (de) | N-Oxidanthranylamid-Derivate und deren Verwendung als Arzneimittel (II) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ KZ KG MD TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): BY RU |